Compensation mechanisms involving these two branches of the pathway could bypass PI3K blockade, but combination targeting of both EGFR and PI3Kβ suppressed ribosomal protein S6 phosphorylation and exerted anti‐tumor activity both in vitro and in vivo, suggesting a new potential therapeutic strategy for PTEN‐null TNBC. Here, PIK3CB is linked to neoplasm.